Saliha Sunkak

Saliha Sunkak

Auto-generated profile, based on publicly available information

Saliha Sunkak

Department of Rheumatology, Kayseri City Hospital, Kayseri, Turkey

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2025 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
NLNihal Lermi
Nihal Lermi
AEALİ EKİN
ALİ EKİN
BYBurcu Yagiz
Burcu Yagiz
FYFatih Yıldırım
Fatih Yıldırım
FAFatih Albayrak
Fatih Albayrak
EDEdiz Dalkılıç
Ediz Dalkılıç

Verified
Journal Article
Open access
PDF file
TOTuğba OCAK
Tuğba OCAK
BYBurcu Yagiz
Burcu Yagiz
BCBelkis Nihan Coşkun
Belkis Nihan Coşkun
GAGamze Akkuzu
Gamze Akkuzu
AAAyşe Nur Bayındır Akbaş
Ayşe Nur Bayındır Akbaş
YPYavuz Pehlivan
Yavuz Pehlivan
Background: Secukinumab is a fully human monoclonal antibody that targets interleukin (IL)-17A and is used to treat axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). Treating axSpA and PsA can be challenging in patients with comorbidities. In this multicenter retrospective study, we aimed to evaluate the efficacy and safety of secukinumab treatment in patients with axSpA and PsA who had a history of tuberculosis, multiple sclerosis (MS), or congestive heart failure (CHF). Methods: The study included 44 patients with a diagnosis of axSpA and PsA and a history of tuberculosis, MS, or CHF who received secukinumab treatment at 13 centers in our country. Erythrocyte sedimentation rate, C-reactive protein (CRP), Bath Ankylosing Spondylitis Disease Activity Index, Ankylosing Spondylitis Disease Activity Score CRP, visual analog scale, and Disease Activity Score-28 CRP markers at months 0, 3, and 12 of secukinumab treatment were analyzed. Alongside this, tuberculosis, MS, and CHF were evaluated at follow-up using clinical assessments and imaging methods such as chest radiographs, brain magnetic resonance, and echocardiography. Results: A statistically significant improvement in inflammatory markers and disease activity scores was observed in patients treated with secukinumab. There was no reactivation in patients with a history of tuberculosis. In most MS patients, the disease was stable, while clinical and radiological improvement was observed in one patient. No worsening of CHF stage was observed in patients with a history of CHF. Conclusions: With regular clinical monitoring, secukinumab may be an effective and safe treatment option for axSpA and PsA patients with a history of tuberculosis, MS, or CHF.

20 April 2025 in Journal of Clinical Ultrasound
Verified
Journal Article
Closed access
SKSinan Karatoprak
Sinan Karatoprak
OAOğuz Aslan
Oğuz Aslan
MBMustafa Bilgili
Mustafa Bilgili
GTGamze Türk
Gamze Türk
HDHüseyin Murat Demirbaş
Hüseyin Murat Demirbaş
SSSaliha Sunkak
Saliha Sunkak

23 June 2025
Verified
Book
Open access
PDF file
GCGizem Cengiz
Gizem Cengiz
GKGizem Kırmızıer
Gizem Kırmızıer
JPJelena Petrovic
Jelena Petrovic
MRMarija Milan Radomirovic
Marija Milan Radomirovic
IDIvana Petrovic Djordjevic
Ivana Petrovic Djordjevic
NYNurdan Yıldırım
Nurdan Yıldırım

20 August 2026 in Scandinavian Journal of Rheumatology
Verified
Journal Article
Closed access
MBMA Balcı
MA Balcı
ZYZ Yağbasan
Z Yağbasan
IGİ Gunduz
İ Gunduz
AAAN Bayindir Akbaş
AN Bayindir Akbaş
FAFatih Albayrak
Fatih Albayrak
GCGozde Yildirim Cetin
Gozde Yildirim Cetin
Systemic sclerosis (SSc), also known as scleroderma, is a rare and complex autoimmune connective tissue disease. It is characterized by progressive fibrosis, vascular abnormalities, and severe comp...

1 January 2026 in The Anatolian Journal of Cardiology
Verified
Journal Article
Closed access
MAMehmet Zafer AYDIN
Mehmet Zafer AYDIN
ZKZülfiye KUZU
Zülfiye KUZU
MTMehmet Kamil TEBER
Mehmet Kamil TEBER
YÇYakup Çetinkaya
Yakup Çetinkaya
ÖŞÖzlem Şen
Özlem Şen
İTİbrahim Halil Tanboğa
İbrahim Halil Tanboğa
Objective: To compare endothelial function, carotid remodeling, renal microvascular injury, and nailfold capillaroscopy across control, dipper, and non-dipper participants and to test whether non-dipper hypertension reflects isolated nocturnal blood pressure dysregulation or broader vascular alteration. Methods: This cross-sectional study included 74 normotensive controls and 157 treatment-naive patients with newly diagnosed essential hypertension, classified by ambulatory monitoring as dipper (n = 70) or non-dipper (n = 87). All underwent flow-mediated dilation, carotid intimamedia thickness, urinary albumin-to-creatinine ratio, and nail-fold capillaroscopy. Regression models adjusted for age, sex, body mass index, diabetes mellitus, and 24-hour systolic blood pressure. Results: Twenty-four-hour systolic blood pressure did not differ between dipper and non-dipper hypertension (143.1 vs. 146.5 mmHg; P = .161), whereas nighttime systolic blood pressure was markedly higher in non-dippers (121.8 vs. 144.5 mmHg; P < .001). Non-dippers had lower flow-mediated dilation (−2.5 [−4.5, 0.8] vs. 3.0 [−2.5, 5.6]%; P < .001); higher carotid intima-media thickness (1.01 [0.86, 1.06] vs. 0.85 [0.67, 1.01] mm; P < .001); and more frequent dilated capillaries (43.0% vs 20.0%; P = .003), microhemorrhages (31.4% vs 15.7%; P = .026), retinopathy (36.1% vs. 19.4%; P = .030), and left ventricular hypertrophy (47.4% vs. 30.9%; P = .044). Capillary density did not differ. After adjustment, non-dipper status remained associated with flow-mediated dilation (−4.22 percentage points; 95% CI, −7.15 to −1.30), carotid intima-media thickness (0.087 mm; 0.025-0.149), and dilated capillaries (odds ratio, 3.17; 1.50-6.71). The carotid association was directionally consistent across measurement-scale strata but significant only among measurements not requiring unit conversion. Conclusion: Non-dipper hypertension identified a multilevel vascular phenotype not explained by 24-hour pressure load and without capillary rarefaction.